Trials / Recruiting
RecruitingNCT07158437
Phase 1 Study of SL-325 in Healthy Volunteers
A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Shattuck Labs, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This first-in-human study is a randomized, double-blind, placebo-controlled, single-ascending dose and multiple-ascending dose study of SL-325 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SL-325 | DR3 blocking antibody |
| OTHER | Placebo (Normal Saline) | Normal saline |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2025-09-05
- Last updated
- 2025-09-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07158437. Inclusion in this directory is not an endorsement.